The main reasons for amyloid PET in our cohort were the clinical suspicion of AD accompanied by unclear or negative CSF findings, the absence of CSF biomarkers (due to contraindications, patient refusal or technical difficulties) and an ambiguous clinical presentation in the context of a CSF profile indicative of AD (low Aβ1-42 and elevated tau). This evidence concerns the gene MAPT and Alzheimer disease.